Affigen, a St. Louis, Missouri-based biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, closed a $17m Series A financing.
The round was led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC.
The company intends to use the proceeds to advance its lead programs through pre-clinical validation and into Phase 1 clinical studies in several hematological malignancies.
Founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies and led by Carlos F. Santos, Ph.D., CEO, Affigen develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers.
The company is headquartered in the Cortex Innovation District in St. Louis, Missouri.